Advancing Truth in Oncology by Complementing Clinical Trials with Evidence from Clinical Practice
JAMA Oncology, ISSN: 2374-2445, Vol: 10, Issue: 4, Page: 433-434
2024
- 4Captures
- 3Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures4
- Readers4
- Mentions3
- News Mentions3
- News3
Most Recent News
Can we drop chemo in older patients with NSCLC?
The combination of chemotherapy and immune checkpoint inhibitor (ICI) therapy does not improve survival compared to ICI alone but increases toxicity in older patients with
Article Description
JAMA Oncology
Bibliographic Details
American Medical Association (AMA)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know